HC Wainwright & Co. Reiterates Buy on Prime Medicine, Maintains $8 Price Target
Prime Medicine, Inc. (PRME) Reports Q3 Loss, Lags Revenue Estimates
Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Prime Medicine Reports Third Quarter 2026 Financial Results and Provides Business Updates
Prime Medicine Q3 EPS $(0.22) Beats $(0.25) Estimate, Sales $4.213M Beat $1.206M Estimate
Prime Medicine Announces Pricing of Public Offering of Common Stock
Prime Medicine Announces Proposed $125.0 Million Public Offering of Common Stock
Prime Medicine Commences $125M Offering Of Common Shares
Prime Medicine to Present at Jefferies Global Healthcare Conference
PRME, BEAM, EDIT, NTLA, CRSP Stocks Gain As FDA Signals Faster Route For Patient-Specific Gene Edits
Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease
Prime: A Buy Due To BLA Filing H1 '27 And Continued PM647 Advancement
Prime Medicine Gets FDA Green Light for Gene Editing Study
Prime Medicine stock surges on FDA IND clearance
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency
FDA Clears Prime Medicine’s IND Application For PM647, Investigational In Vivo Prime Editor For Alpha-1 Antitrypsin Deficiency
Prime Medicine, Inc. (PRME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Prime Medicine to Participate in Upcoming Investor Conferences
BMO Capital Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $9
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.